New drug combo aims to fight rare sarcoma

NCT ID NCT07650838

Not yet recruiting Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests two drugs, OVV-01 and AK112, given together every two weeks to 40 adults with advanced soft tissue sarcoma that has not responded to standard treatments. The main goal is to see if the combination can shrink tumors safely. Researchers will also measure how long any response lasts and how long patients live without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OVV-01 injection and AK112 injection (drug combination)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced soft tissue sarcoma who have run out of standard therapies.
What could go wrong: This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (STS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA (STS)

More trials for these conditions

Other studies related to the condition(s) this trial covers.